

Aeglea BioTherapeutics, Inc.  
Form S-8  
April 07, 2016

As filed with the Securities and Exchange Commission on April 7, 2016

Registration No. 333-

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**WASHINGTON, D.C. 20549**

**FORM S-8**  
**REGISTRATION STATEMENT**  
***UNDER***  
***THE SECURITIES ACT OF 1933***

**AEGLEA BIOTHERAPEUTICS, INC.**

(Exact name of Registrant as specified in its charter)

**Delaware**  
**(State or other jurisdiction of**  
**incorporation or organization)**

**901 S. MoPac Expressway**

**Barton Oaks Plaza One**

**46-4312787**  
**(I.R.S. Employer**  
**Identification Number)**

Edgar Filing: Aeglea BioTherapeutics, Inc. - Form S-8

**Suite 250**

**Austin, TX 78746**

**(512) 942-2935**

(Address, including zip code, and telephone number, including area code, of Registrant's principal executive offices)

**2016 Equity Incentive Plan**

**2016 Employee Stock Purchase Plan**

**2015 Equity Incentive Plan**

**(Full title of the plans)**

**David G. Lowe, Ph.D.**

**Chief Executive Officer**

**Aeglea BioTherapeutics, Inc.**

**901 S. MoPac Expressway**

**Barton Oaks Plaza One**

**Suite 250**

**Austin, TX 78746**

**(512) 942-2935**

(Name, address, including zip code, and telephone number, including area code, of agent for service)

*Please send copies of all communications to:*

**Robert A. Freedman, Esq.**

**Fenwick & West LLP**

**555 California Street**

**San Francisco, CA 94104**

**(415) 875-2300**

Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company (as defined in Rule 12b-2 of the Exchange Act):

Large Accelerated Filer  Accelerated Filer   
 Non-accelerated Filer  (Do not check if a smaller reporting company) Smaller Reporting Company

**CALCULATION OF REGISTRATION FEE**

Title of Each Class of Securities to be Registered	Amount to be Registered(1)	Proposed	Proposed	Amount of Registration Fee
		Maximum Offering Price Per Unit	Maximum Aggregate Offering Price	
Common Stock, \$0.0001 par value				
-- To be issued under the 2016 Equity Incentive Plan	1,609,869(2)	\$10.00(3)	\$16,098,690	\$1,622
-- To be issued under the 2016 Employee Stock Purchase Plan	165,000	\$8.50(4)	\$1,402,500	\$142
-- Outstanding under the 2015 Equity Incentive Plan	714,265(5)	\$4.66(6)	\$3,328,475	\$336
<b>Total</b>	<b>2,489,134</b>		<b>\$20,829,665</b>	<b>\$2,100</b>

- (1) Pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the *Securities Act*), this Registration Statement shall also cover any additional shares of the Registrant's common stock that become issuable under the Registrant's 2016 Equity Incentive Plan, 2016 Employee Stock Purchase Plan or 2015 Equity Incentive Plan by reason of any stock dividend, stock split, recapitalization or other similar transaction effected without the receipt of consideration that increases the number of the Registrant's outstanding shares of common stock.
- (2) Shares of common stock reserved for issuance under the 2016 Equity Incentive Plan consists of (a) 1,100,000 shares of common stock reserved for future issuance under the 2016 Equity Incentive Plan and (b) 509,869 shares of common stock previously reserved but unissued under the 2015 Equity Incentive Plan on the effective date of the 2016 Equity Incentive Plan that are now available for issuance under the 2016 Equity Incentive Plan. In addition, any shares subject to outstanding awards under the 2015 Equity Incentive Plan that are issuable upon the exercise of options that expire without having been exercised in full, are forfeited or repurchased by the Registrant at the original purchase price, or are used to pay the exercise price or withholding obligations related to any award, will be available for future grant and issuance under the 2016 Equity Incentive Plan.
- (3) Estimated solely for the purpose of calculating the registration fee in accordance with Rules 457(h) under the Securities Act and based upon the initial public offering price of \$10.00.
- (4)

Edgar Filing: Aeglea BioTherapeutics, Inc. - Form S-8

- Estimated solely for the purpose of calculating the registration fee in accordance with Rules 457(h) under the Securities Act and based upon the initial public offering price of \$10.00, multiplied by 85%, which is the percentage of the trading price per share applicable to purchasers under the 2016 Employee Stock Purchase Plan.
- (5) Represents shares of common stock reserved for issuance pursuant to outstanding stock option awards under the 2015 Equity Incentive Plan.
  - (6) Estimated solely for the purpose of calculating the registration fee in accordance with Rule 457(h) under the Securities Act on the basis of the weighted average exercise price of \$4.66 per share (rounded up to the nearest cent).

**PART I**

**INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS**

The information required under Part I of Form S-8 is omitted from this Registration Statement in accordance with Rule 428 of the Securities Act of 1933, as amended (the Securities Act ), and the instructions to Form S-8. In accordance with the rules and regulations of the Securities and Exchange Commission (the Commission ) and the instructions to Form S-8, such documents are not being filed with the Commission either as part of this Registration Statement or as prospectuses or prospectus supplements pursuant to Rule 424.

## PART II

### INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

#### Item 3. Incorporation of Documents by Reference.

The following documents filed by the Registrant with the Commission pursuant to the Securities Act and the Securities Exchange Act of 1934, as amended (the Exchange Act ) are incorporated herein by reference:

- (a) the Registrant's prospectus to be filed pursuant to Rule 424(b) under the Securities Act relating to the Registration Statement on Form S-1, as amended (File No. 333-205001), which contains audited financial statements for the Registrant's latest fiscal year for which such statements have been filed; and
- (b) The description of the Registrant's common stock contained in the Registrant's registration statement on Form 8-A (File No. 001-37722) filed on March 28, 2016 under Section 12(b) of the Exchange Act, including any amendment or report filed for the purpose of updating such description.

All documents filed by the Registrant pursuant to Section 13(a), 13(c), 14 or 15(d) of the Exchange Act subsequent to the filing of this Registration Statement and prior to the filing of a post-effective amendment which indicates that all securities offered hereby have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference into this Registration Statement and to be a part hereof from the date of filing such documents, except as to specific sections of such documents as set forth therein. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained in any subsequently filed document which also is deemed to be incorporated by reference herein modifies or supersedes such statement.

#### Item 4. Description of Securities.

Not applicable.

#### Item 5. Interests of Named Experts and Counsel.

Not applicable.

#### Item 6. Indemnification of Directors and Officers.

The Registrant is incorporated under the laws of the State of Delaware. Section 145 of the Delaware General Corporation Law authorizes a court to award, or a corporation's board of directors to grant, indemnity to directors and officers under certain circumstances and subject to certain limitations. The terms of Section 145 of the Delaware General Corporation Law are sufficiently broad to permit indemnification under certain circumstances for liabilities, including reimbursement of expenses incurred, arising under the Securities Act.

As permitted by the Delaware General Corporation Law, the Registrant's restated certificate of incorporation includes a provision that eliminates, to the fullest extent permitted by law, the personal liability of a director for monetary damages resulting from breach of his fiduciary duty as a director, except for liability:

for any breach of the director's duty of loyalty to the Registrant or its stockholders;

for acts or omissions not in good faith or that involve intentional misconduct or a knowing violation of law;

under Section 174 of the Delaware General Corporation Law (regarding unlawful dividends, stock purchases or redemptions); or

for any transaction from which the director derived an improper personal benefit

As permitted by the Delaware General Corporation Law, the Registrant's bylaws provide that:

the Registrant is required to indemnify its directors and officers to the fullest extent permitted by the Delaware General Corporation Law, subject to certain very limited exceptions;

the Registrant may indemnify its other employees and agents as set forth in the Delaware General Corporation Law;

the Registrant is required to advance expenses, as incurred, to its directors and officers in connection with a legal proceeding to the fullest extent permitted by the Delaware General Corporation Law, subject to certain very limited exceptions; and

the rights conferred in the restated bylaws are not exclusive.

In addition, the Registrant has entered, and intends to continue to enter, into indemnity agreements with each of its current directors and executive officers. These agreements will provide for the indemnification of directors and executive officers for all reasonable expenses and liabilities incurred in connection with any action or proceeding brought against them by reason of the fact that they are or were agents of the Registrant.

The Registrant currently carries liability insurance for its directors and executive officers for securities matters.

The indemnification provisions in the Registrant's restated certificate of incorporation and restated bylaws and the indemnification agreements entered into or to be entered into between the Registrant and each of its directors and executive officers is sufficiently broad to permit indemnification of the Registrant's directors and executive officers for liabilities arising under the Securities Act.

See also the undertakings set out in response to Item 9 hereof.

#### **Item 7. Exemption From Registration Claimed.**

Not applicable.

#### **Item 8. Exhibits.**

The following exhibits are filed herewith:

<b>Exhibit Number</b>	<b>Exhibit Description</b>	<b>Incorporated by Reference</b>				<b>Filed Herewith</b>
		<b>Form</b>	<b>File No.</b>	<b>Exhibit</b>	<b>Filing Date</b>	
4.1	Form of Restated Certificate of Incorporation of the Registrant	S-1	333-205001	3.2	9/14/2015	
4.2	Form of Restated Bylaws of the Registrant	S-1	333-205001	3.4	9/14/2015	
4.3	Form of Registrant's Common Stock certificate	S-1	333-205001	4.1	9/14/2015	
5.1	Opinion of Fenwick & West LLP					X
23.1	Consent of Fenwick & West LLP (contained in Exhibit 5.1)					X
23.2	Consent of PricewaterhouseCoopers LLP, independent registered public accounting firm					X
24.1	Power of Attorney (included on the signature page to this Registration Statement)					X
99.1	2015 Equity Incentive Plan and forms of stock option agreement and stock option exercise agreement	S-1	333-205001	10.2	6/16/2015	
99.2	2016 Equity Incentive Plan and forms of stock option agreement and stock option	S-1	333-205001	10.3	3/28/2016	



exercise agreement

99.3 2016 Employee Stock Purchase Plan S-1 333-205001 10.4 3/28/2016

**Item 9. Undertakings.**

A. The undersigned Registrant hereby undertakes:

(1) To file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:

(i) To include any prospectus required by Section 10(a)(3) of the Securities Act;

(ii) To reflect in the prospectus any facts or events arising after the effective date of the Registration Statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the Registration Statement. Notwithstanding the foregoing, any increase or decrease in the volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and

any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20 percent change in the maximum aggregate offering price set forth in the Calculation of Registration Fee table in the effective Registration Statement;

(iii) To include any material information with respect to the plan of distribution not previously disclosed in the Registration Statement or any material change to such information in the Registration Statement;

provided, however, that paragraphs (a)(1)(i) and (a)(1)(ii) above do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in periodic reports filed with or furnished to the Commission by the Registrant pursuant to Section 13 or Section 15(d) of the Exchange Act that are incorporated by reference in the Registration Statement.

(2) That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial *bona fide* offering thereof.

(3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

B. The undersigned Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the Registrant's annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan's annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in the Registration Statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial *bona fide* offering thereof.

C. Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered hereby, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

**SIGNATURES**

Pursuant to the requirements of the Securities Act, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in Austin, Texas, on this 6th day of April, 2016.

**AEGLEA BIOTHERAPEUTICS, INC.**

By: /s/ David G. Lowe, Ph.D.  
David G. Lowe, Ph.D.

President, Chief Executive Officer and  
Director

**POWER OF ATTORNEY**

**KNOW ALL PERSONS BY THESE PRESENTS**, that each person whose signature appears below hereby constitutes and appoints David G. Lowe and Charles N. York II, and each of them, as his or her true and lawful attorney-in-fact and agent with full power of substitution, for him or her in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement on Form S-8, and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully for all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent, or his or her substitute, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act, this Registration Statement has been signed by the following persons in the capacities and on the date indicated.

<b>Signature</b>	<b>Title</b>	<b>Date</b>
/s/ David G. Lowe, Ph.D.	President, Chief Executive Officer and Director	April 6, 2016
David G. Lowe, Ph.D.	(Principal Executive Officer)	
/s/ Charles N. York II	Chief Financial Officer and Vice President	April 6, 2016
Charles N. York II	(Principal Accounting Officer and Principal Financial Officer)	
/s/ Russell J. Cox	Director	April 6, 2016
Russell J. Cox		
/s/ George Georgiou, Ph.D.	Director	April 6, 2016

Edgar Filing: Aeglea BioTherapeutics, Inc. - Form S-8

George Georgiou, Ph.D.

/s/ Sandesh Mahatme

Director

April 6, 2016

Sandesh Mahatme, LLM

/s/ Anthony G. Quinn, M.B Ch.B, Ph.D.

Director

April 6, 2016

Anthony G. Quinn, M.B Ch.B, Ph.D.

/s/ Armen Shanafelt, Ph.D.

Director

April 6, 2016

Armen Shanafelt, Ph.D.

---

**EXHIBIT INDEX**

<b>Exhibit Number</b>	<b>Exhibit Description</b>	<b>Incorporated by Reference</b>				<b>Filed Herewith</b>
		<b>Form</b>	<b>File No.</b>	<b>Exhibit</b>	<b>Filing Date</b>	
4.1	Form of Restated Certificate of Incorporation of the Registrant	S-1	333-205001	3.2	9/14/2015	
4.2	Form of Restated Bylaws of the Registrant	S-1	333-205001	3.4	9/14/2015	
4.3	Form of Registrant's Common Stock certificate	S-1	333-205001	4.1	9/14/2015	
5.1	Opinion of Fenwick & West LLP					X
23.1	Consent of Fenwick & West LLP (contained in Exhibit 5.1)					X
23.2	Consent of PricewaterhouseCoopers LLP, independent registered public accounting firm					X
24.1	Power of Attorney (included on the signature page to this Registration Statement)					X
10.2	2015 Equity Incentive Plan and forms of stock option agreement and stock option exercise agreement	S-1	333-205001	10.2	6/16/2015	
10.3	2016 Public Company Equity Incentive Plan and forms of stock option agreement and stock option exercise agreement	S-1	333-205001	10.3	3/28/2016	
10.4	2016 Employee Stock Purchase Plan	S-1	333-205001	10.4	3/28/2016	